

# Norman L Foster

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7166367/publications.pdf>

Version: 2024-02-01

21  
papers

1,756  
citations

758635

12  
h-index

839053

18  
g-index

22  
all docs

22  
docs citations

22  
times ranked

2956  
citing authors

#	ARTICLE	IF	CITATIONS
1	FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. <i>Brain</i> , 2007, 130, 2616-2635.	3.7	508
2	The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. <i>Alzheimer's and Dementia</i> , 2010, 6, 221-229.	0.4	464
3	The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. <i>Alzheimer's and Dementia</i> , 2015, 11, 757-771.	0.4	199
4	Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 474.	0.4	176
5	The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data. <i>Alzheimer's and Dementia</i> , 2015, 11, 1050-1068.	0.4	98
6	Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 $\beta$ -Amyloid Measures Across the Spectrum of Alzheimer Disease. <i>JAMA Neurology</i> , 2015, 72, 571.	4.5	87
7	Overexpression of Mutant Amyloid- $\beta$ Protein Precursor and Presenilin 1 Modulates Enteric Nervous System. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 1263-1278.	1.2	57
8	Clinical use of amyloid $\beta$ -positron emission tomography neuroimaging: Practical and bioethical considerations. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 358-367.	1.2	33
9	Quality improvement in neurology. <i>Neurology</i> , 2019, 93, 705-713.	1.5	29
10	Realizing the potential of positron emission tomography with $^{18}\text{F}$ -fluorodeoxyglucose to improve the treatment of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2008, 4, S29-36.	0.4	25
11	Short-Term Practice Effects and Brain Hypometabolism: Preliminary Data from an FDG PET Study. <i>Archives of Clinical Neuropsychology</i> , 2015, 30, 264-270.	0.3	17
12	Evaluating the Impact of Cochlear Implantation on Cognitive Function in Older Adults. <i>Laryngoscope</i> , 2022, 132, .	1.1	16
13	Relationship between $^{18}\text{F}$ -Flutemetamol uptake and RBANS performance in non-demented community-dwelling older adults. <i>Clinical Neuropsychologist</i> , 2017, 31, 531-543.	1.5	13
14	Coverage With Evidence Development. <i>JAMA Neurology</i> , 2014, 71, 399.	4.5	9
15	Overall and sex-specific risk factors for subjective cognitive decline: findings from the 2015-2018 Behavioral Risk Factor Surveillance System Survey. <i>Biology of Sex Differences</i> , 2022, 13, 16.	1.8	9
16	Justifying reimbursement for Alzheimer's diagnostics and treatments: Seeking alignment on evidence. , 2014, 10, 503-508.		6
17	Changes in the Auditory Association Cortex in Dementing Illnesses. <i>Otology and Neurotology</i> , 2020, 41, 1327-1333.	0.7	6
18	How good are medical and death records for identifying dementia?. <i>Alzheimer's and Dementia</i> , 2022, 18, 1812-1823.	0.4	3

#	ARTICLE	IF	CITATIONS
19	The impact of $\text{Î}^2$ -amyloid positron emission tomography on the diagnostic and treatment decisions of dementia experts. <i>Neurodegenerative Disease Management</i> , 2017, 7, 107-117.	1.2	1
20	Strategies for using Molecular Neuroimaging in Dementia. <i>Handbook of Clinical Neurology</i> / Edited By PJ Vinken and G W Bruyn, 2008, 89, 87-95.	1.0	0
21	Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Innovations in care that advance Alzheimer's disease drug development. , 2009, 5, 159-162.		0